Program Schedule

326
Antimicrobial co-resistance patterns of gram-negative bacilli isolated from bloodstream infections: a longitudinal epidemiological study from 2002-2011

Session: Poster Abstract Session: Multidrug-resistant Organisms: Epidemiology and Prevention
Thursday, October 9, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
Posters
  • GNB Poster final.pdf (938.2 kB)
  • Background: Increasing multidrug resistance in gram-negative bacilli (GNB) infections poses a serious threat to public health. Few studies have analyzed co-resistance rates in detail, defined as an antimicrobial susceptibility profile in a subset resistant to one specific antibiotic. The epidemiologic and clinical utility of determining co-resistance rates are analyzed and discussed.

    Methods: A 10-year retrospective study from 2001-2011 of bloodstream infections with GNB were analyzed from three hospitals in Greater Vancouver, BC, Canada. Descriptive statistics were calculated for antimicrobial resistance and co-resistance. Statistical analysis further described temporal trends of antimicrobial resistance, correlations of resistance between combinations of antimicrobials, and temporal trends in co-resistance patterns.

    Results: The total number of unique blood stream isolates of GNB was 3280. Increasing resistance to individual antimicrobials was observed for E. coli, K. pneumoniae, K. oxytoca, E. cloacae, and P. aeruginosa. Ciprofloxacin resistance in E. coli peaked in 2006 at 40% and subsequently stabilized at 29% in 2011, corresponding to decreasing ciprofloxacin usage after 2007 as assessed by daily defined dose utilization data. High co-resistance rates were observed for ceftriaxone-resistant E. coli with ciprofloxacin (73%), ceftriaxone-resistant K. pneumoniae with trimethoprim-sulfamethoxazole (83%), ciprofloxacin-resistant E. cloacae with ticarcillin-clavulanate (91%), and piperacillin-tazobactam-resistant P. aeruginosa with ceftazidime (83%).

    Conclusion: Increasing antimicrobial resistance was demonstrated over the study period, and may partially be associated with antimicrobial consumption. The study of co-resistance rates in multidrug resistant GNB provides insight into the epidemiology of resistance pattern development, and can be used as a clinical tool to aid prescribing empiric antimicrobial therapy.

    Patrick Wong, MD1, Marcus Von Krosigk, BSc(Pharm), ACPR, DPhil(Oxon.)2, Diane Roscoe, MD FRCPC3, Tim T.Y. Lau, PharmD4, Masoud Yousefi, MSc5 and William R. Bowie, MD, FRCPC1, (1)Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, (2)Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, (3)Pathology and Laboratory Medicine, Vancouver Coastal Health, Vancouver, BC, Canada, (4)Pharmaceutical Sciences, Vancouver General Hospital, Vancouver Coastal Health, Vancouver, BC, Canada, (5)Brain Research Centre, University of British Columbia, Vancouver, BC, Canada

    Disclosures:

    P. Wong, None

    M. Von Krosigk, None

    D. Roscoe, None

    T. T. Y. Lau, None

    M. Yousefi, None

    W. R. Bowie, None

    Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

    Sponsoring Societies:

    © 2014, idweek.org. All Rights Reserved.

    Follow IDWeek